Northwest Biotherapeutics (OTCMKTS:NWBO) Shares Cross Below 200-Day Moving Average – Here’s What Happened

Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO)’s share price crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.25 and traded as low as $0.23. Northwest Biotherapeutics shares last traded at $0.2330, with a volume of 2,464,645 shares changing hands.

Northwest Biotherapeutics Stock Performance

The firm has a market cap of $371.74 million, a price-to-earnings ratio of -0.01 and a beta of -0.86. The stock’s 50 day simple moving average is $0.26 and its 200-day simple moving average is $0.25.

Northwest Biotherapeutics Company Profile

Northwest Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of personalized dendritic cell immunotherapies for the treatment of cancer. The company’s proprietary platform harnesses patient-derived dendritic cells to present tumor-specific antigens and stimulate a targeted immune response. By tailoring each vaccine to the individual patient’s tumor profile, the approach aims to improve outcomes and reduce off-target toxicity associated with conventional therapies.

The company’s lead candidate, DCVax®-L, is designed for patients with newly diagnosed or recurrent glioblastoma multiforme (GBM) and has advanced through a global Phase III clinical trial.